A Long-Term, Open-Label, Study on Schizophrenia

1. Is the biology right?

• Somatic driver evidence: no · None of GRM2, GRM3, HTR2A, HTR2C, DRD2, HTR1A has somatic-mutation evidence in schizophrenia

  Rule: Open Targets has somatic-mutation evidence for the target in this cancer. Source: Open Targets: GRM2 in schizophrenia, 2026-11-12
• Human genetic evidence: yes · GRM3: germline; DRD2: germline

  Rule: Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence. Source: Open Targets: GRM3 in schizophrenia, 2026-11-12

  Published context: 2.6× relative probability of success, phase 1 to launch, with human genetic support (Minikel et al., Nature 2024, drug programs to 2023). All therapy areas, mostly germline evidence; not a probability for this program.
• Pediatric target: no · Not on the FDA list

  Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study. Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
• Haematologic cancer: no · Solid tumour

  Rule: From the indication, or the registry conditions when no indication matches. Source: ClinicalTrials.gov NCT01129674, 2026-11-12

  Published context: Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid (BIO / Informa / QLS 2021, 2011–2020). Population-level, not a prediction.

• GRM2 (via LY2140023): Evidence types in schizophrenia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc. · Open Targets: GRM2 in schizophrenia
• GRM3 (via LY2140023): Evidence types in schizophrenia: literature, genetic_association, clinical; literature listed separately from human genetics. Datasources: gwas_credible_sets, clinical_precedence, europepmc. · Open Targets: GRM3 in schizophrenia
• HTR2A (via Olanzapine): Evidence types in schizophrenia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc. · Open Targets: HTR2A in schizophrenia
• HTR2C (via Olanzapine): Evidence types in schizophrenia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc. · Open Targets: HTR2C in schizophrenia
• DRD2 (via Olanzapine): Evidence types in schizophrenia: literature, animal_model, genetic_association, clinical; literature and animal_model listed separately from human genetics. Datasources: clinical_precedence, gwas_credible_sets, europepmc, impc, eva. · Open Targets: DRD2 in schizophrenia
• HTR1A (via Aripiprazole): Evidence types in schizophrenia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc. · Open Targets: HTR1A in schizophrenia

• Not loaded on this app yet: Normal-tissue expression in vital organs. Source: Human Protein Atlas (ticket 36).
• Not loaded on this app yet: Pan-essential in cell lines. Source: DepMap (ticket 36).
• Not loaded on this app yet: Approved drug on this target. Source: Drugs@FDA (ticket 30).

2. Can the result be trusted?

• Randomised: yes · Randomised allocation

  Rule: Registry allocation field. Source: ClinicalTrials.gov NCT01129674, 2026-11-12
• Small denominator: no · 560 enrolled; each patient moves a rate by 100 ÷ 560 = 0.2 points

  Rule: Enrolment under 30; the arithmetic is shown, not a benchmark. Source: ClinicalTrials.gov NCT01129674, 2026-11-12
• Primary endpoint is overall survival: no · Time to discontinuation due to adverse events

  Rule: A registered primary outcome measure names overall survival. Source: ClinicalTrials.gov NCT01129674, 2026-11-12

  Published context: Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3 (Otsuka 2021, 400 phase 3 oncology trials, to 2020). Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival.

  Published context: 52% of surrogate-to-OS correlations are low (Prasad 2015, published to 2014). Shown with the figure above.
• Results overdue: yes · Primary completion 2012-10, 169 months ago; no results posted

  Rule: Primary completion (actual) more than 12 months ago and no results posted to the registry. Source: ClinicalTrials.gov NCT01129674, 2026-11-12

  Published context: 40.9% of applicable trials report results within a year (Results-reporting studies summarised in spec §11, all therapy areas). All areas, not oncology only.

• Not loaded on this app yet: Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff. Source: Readout extraction (ticket 32).
• Not loaded on this app yet: Primary endpoint changed between registry versions. Source: Registry versions in the store (ticket 32).

3. What must it beat?

• Not loaded on this app yet: Control-arm result and approved therapies for the same segment, with label links. Source: Drugs@FDA, FDA labels and readouts (tickets 30, 32).

4. Too crowded, or too late?

• Stopped on this target: 2 terminated, withdrawn or suspended trials of drugs against GRM2. Reasons are quoted as the registry gives them on the target page. · GRM2: what already stopped

• Not loaded on this app yet: Programs on the target by phase and months behind the leader. Source: Programs and Drugs@FDA (ticket 33).

5. Can it be approved, and stay approved?

• Single-country: no · 81 sites in 9 countries; 42 in the United States (52%)

  Rule: All listed sites are in one country; the share of US sites is shown. Source: ClinicalTrials.gov NCT01129674, 2026-11-12
• EU paediatric investigation plan: yes · EMEA-000150-PIP02-10 ((1R, 4S, 5S, 6S)-4-[[(2s)-2-amino-4-(methylthio)-1-oxobutyl]amino]-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid,2,2-dioxide, monohydrate (LY2140023), Treatment of schizophrenia): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 26 Oct 2011; EMEA-000235-PIP02-10-M02 (aripiprazole, Treatment of bipolar affective disorder;Treatment of schizophrenia): PM: decision on the application for modification of an agreed PIP, 26 Oct 2012; compliance positive 24 Jun 2016; EMEA-001034-PIP01-10 (risperidone, Treatment of conduct disorder): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 6 Jul 2011

  Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
• EU orphan designation: no · No EU orphan designation names LY2140023, Olanzapine, Aripiprazole, Risperidone

  Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
• Authorised in the EU: yes · Aripiprazole Sandoz: authorised since 20 Aug 2015; Olazax: authorised since 11 Dec 2009; Zypadhera: authorised since 19 Nov 2008; Olazax Disperzi: authorised since 10 Dec 2009; +20 more

  Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
• FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link

  Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
• FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of LY2140023, Olanzapine, Aripiprazole, Risperidone

  Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
• Registered studies open to children: yes · 221 interventional studies of LY2140023, Olanzapine, Aripiprazole, Risperidone include patients under 18; 11 are recruiting, not yet recruiting or active

  Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12

• Caveat: Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality.
• Rare pediatric disease voucher: FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. · FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

• Not loaded on this app yet: Precedent approvals for target, modality and endpoint; accelerated-approval status. Source: Drugs@FDA and FDA accelerated-approval tables (ticket 30).

6. Can the sponsor finish?

• Sponsor: Denovo Biopharma LLC (industry) · ClinicalTrials.gov NCT01129674
• study director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company · Person page

• Not loaded on this app yet: Filed cash, quarterly spend and the runway arithmetic. Source: SEC XBRL company facts (ticket 37).
• Not loaded on this app yet: Sponsor's completed vs stopped oncology trials and results-reporting record. Source: Registry, by company (ticket 37).

What public data cannot tell you

Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.